Castle Biosciences to acquire Capsulomics, terms undisclosed

Castle Biosciences (CSTL) announced it has signed a definitive agreement to acquire Capsulomics, d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed. The transaction is expected to close in the coming weeks, subject to the customary closing conditions.